EGb 761 for Mild Cognitive Impairment with CVD
EGb 761 in the Syndrome of MCI With Concomitant CVD
Recruiting
Phase 2
Interventional Study
Mild Cognitive Impairment
Cerebrovascular Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 45 – 85
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 134 (estimated)
- Sponsor
- National Neuroscience Institute · Other
Who this trial is looking for
This trial is looking for adults aged 45 to 85 with mild cognitive impairment and cerebrovascular disease. Participants will receive the treatment EGb 761 and help researchers understand its effects on cognition and safety.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with mild cognitive impairment.
- I have a Global Clinical Dementia Rating Score of 0.5.
- I am between 45 and 85 years old.
- I can read and understand the study requirements.
- I have cerebrovascular disease shown by brain imaging.
- I have given written consent to participate.
You may not be able to join if
- I am currently taking antidepressants.
- I am currently taking antipsychotics.
- I am currently taking benzodiazepines.
- I am currently taking acetylcholinesterase inhibitors.
- I am currently taking NMDA antagonists.
- I have a medical condition that prevents me from taking EGb 761.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients who have been diagnosed with MCI based on the Petersen criteria and Albert MS criteria
* Patients who have a Global Clinical Dementia Rating Score of 0.5
* Patients aged 45 to 85 years at study entry
* Patients who are literate and able to complete the cognitive evalu…
Contacts